Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 12
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Axsome Therapeutics Inc
AXSM
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$168.90
0.55
0.33%
Dern. MÀJ: Oct 12, 9:39 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Axsome Therapeutics Financials
Axsome Therapeutics (AXSM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results
Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.
Avi Kapoor
PRO
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.83) by 19.28 percent. This is a 110.64 percent decrease over losses of $(0.47) per
Benzinga Newsdesk
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock
Axsome (AXSM) Q1: Revenue beats, but wider loss and rising expenses weigh on shares. Get the key data on Sunosi and Auvelity sales.
Vandana Singh
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
Axsome Therapeutics Q1 EPS $(1.26) Misses $(0.90) Estimate, Sales $191.203M Beat $189.193M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.90) by 40 percent. This is a 85.29 percent decrease over losses of $(0.68) per share
Benzinga Newsdesk
PRO
Axsome Therapeutics Q4 EPS $(0.56) Beats $(0.68) Estimate, Sales $195.999M Beat $193.107M Estimate
Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.68) by 17.4 percent. This is a 30 percent increase over losses of $(0.80) per share from
Benzinga Newsdesk
